Skip to main content

azacitidine

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, azacitidine can be made available within NHS Wales for the treatment of progressive angioimmunoblastic T-cell lymphoma.

The risks and benefits of the off-label use of azacitidine for this indication should be clearly stated and discussed with the patient to allow informed consent.

In July 2020 OWMAG recommended this treatment in NHS Wales, in September 2023 there was a review of the recommendation. OWMAG found nothing new that affects the original decision.

This advice will be reviewed after 2 years or earlier if new evidence becomes available.

 One Wales Interim Decision (with start stop criteria and evidence review): Azacitidine for the treatment of progressive angioimmunoblastic T-cell lymphoma (OW16 2023 review) (PDF, 115Kb)

Medicine details

Medicine name azacitidine
Formulation Powder for suspension for injection
Reference number OW16
Indication

For the treatment of progressive angioimmunoblastic T-cell lymphoma

Company Various
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status One Wales interim decision
Date of issue 23/07/2020
Date of last review September 2023
Follow AWTTC: